Today we are happy to announce that we have secured USD 5m funding from new and existing investors in an extended series C round. New funds will be used to extend Biognosys commercial operations and to accelerate the development of next generation proteomics workflows and products for high-content and high-throughput protein analysis.
"The feedback that we get from our customers shows there is a shift in the perception of proteomics, away from a highly specialized analytical tool and towards a universally applicable technology for mode of action studies and biomarker development" says Dr. Oliver Rinner, CEO and co-founder of Biognosys.
He adds: "The funds will help us to further extend our technological lead, to accelerate the development of new products and workflows, and to better address the life science research market outside the classical proteomics field".
More information about the funding is available in the press release (click here for download).